Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
$1.21
+4.3%
$1.10
$0.86
$3.60
$70.26M0.11281,821 shs377,826 shs
HPPI
HedgePath Pharmaceuticals
$0.05
$0.05
$0.04
$0.32
$17.78M-1.1619,283 shsN/A
InterCure Ltd. stock logo
INCR
InterCure
$1.57
+4.7%
$1.53
$1.17
$2.62
$68.36M1.1825,956 shs25,997 shs
VolitionRx Limited stock logo
VNRX
VolitionRx
$0.71
+4.8%
$0.60
$0.40
$0.94
$72.70M1.2206,900 shs160,195 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
+4.31%+9.01%+0.83%+14.15%-47.62%
HPPI
HedgePath Pharmaceuticals
0.00%+2.35%-11.11%-12.73%-40.00%
InterCure Ltd. stock logo
INCR
InterCure
+4.67%+6.08%+4.67%+24.60%-32.03%
VolitionRx Limited stock logo
VNRX
VolitionRx
+4.80%-8.10%+27.38%+42.85%+15.31%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
1.2508 of 5 stars
3.50.00.00.00.01.70.6
HPPI
HedgePath Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
InterCure Ltd. stock logo
INCR
InterCure
N/AN/AN/AN/AN/AN/AN/AN/A
VolitionRx Limited stock logo
VNRX
VolitionRx
1.669 of 5 stars
3.50.00.00.00.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
3.00
Buy$6.33423.42% Upside
HPPI
HedgePath Pharmaceuticals
0.00
N/AN/AN/A
InterCure Ltd. stock logo
INCR
InterCure
0.00
N/AN/AN/A
VolitionRx Limited stock logo
VNRX
VolitionRx
3.00
Buy$3.50395.96% Upside

Current Analyst Ratings Breakdown

Latest HPPI, INCR, VNRX, and ABOS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$4.00
6/10/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$3.00
4/30/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
N/AN/AN/AN/A$3.03 per shareN/A
HPPI
HedgePath Pharmaceuticals
N/AN/AN/AN/A($0.01) per shareN/A
InterCure Ltd. stock logo
INCR
InterCure
$64.55MN/AN/AN/A$2.36 per shareN/A
VolitionRx Limited stock logo
VNRX
VolitionRx
$1.31M55.57N/AN/A($0.11) per share-6.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$102.33M-$1.94N/AN/AN/AN/A-58.24%-46.53%8/12/2025 (Estimated)
HPPI
HedgePath Pharmaceuticals
-$4.55MN/A0.00N/AN/AN/A-246.03%N/A
InterCure Ltd. stock logo
INCR
InterCure
-$18.32MN/A0.00N/AN/AN/AN/A8/28/2025 (Estimated)
VolitionRx Limited stock logo
VNRX
VolitionRx
-$35.32M-$0.27N/AN/A-2,321.14%N/A-163.39%N/A

Latest HPPI, INCR, VNRX, and ABOS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$0.56-$0.48+$0.08-$0.48N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
N/AN/AN/AN/AN/A
HPPI
HedgePath Pharmaceuticals
N/AN/AN/AN/AN/A
InterCure Ltd. stock logo
INCR
InterCure
N/AN/AN/AN/AN/A
VolitionRx Limited stock logo
VNRX
VolitionRx
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
0.19
8.02
8.02
HPPI
HedgePath Pharmaceuticals
N/A
6.76
6.76
InterCure Ltd. stock logo
INCR
InterCure
0.34
1.73
1.18
VolitionRx Limited stock logo
VNRX
VolitionRx
N/A
0.22
0.22

Institutional Ownership

CompanyInstitutional Ownership
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
71.01%
HPPI
HedgePath Pharmaceuticals
N/A
InterCure Ltd. stock logo
INCR
InterCure
8.34%
VolitionRx Limited stock logo
VNRX
VolitionRx
8.09%

Insider Ownership

CompanyInsider Ownership
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
7.10%
HPPI
HedgePath Pharmaceuticals
4.80%
InterCure Ltd. stock logo
INCR
InterCure
N/A
VolitionRx Limited stock logo
VNRX
VolitionRx
10.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
2060.57 million56.27 millionOptionable
HPPI
HedgePath Pharmaceuticals
1370.45 millionN/ANot Optionable
InterCure Ltd. stock logo
INCR
InterCure
350N/AN/AOptionable
VolitionRx Limited stock logo
VNRX
VolitionRx
80103.02 million80.80 millionOptionable

Recent News About These Companies

VolitionRX shares hold as Benchmark maintains rating
VolitionRx initiated with a Buy at H.C. Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Acumen Pharmaceuticals stock logo

Acumen Pharmaceuticals NASDAQ:ABOS

$1.21 +0.05 (+4.31%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$1.24 +0.03 (+2.07%)
As of 08:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

HedgePath Pharmaceuticals OTCMKTS:HPPI

$0.05 0.00 (0.00%)
As of 07/7/2025

HedgePath Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers and non-cancerous proliferation disorders in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It also develops super bioavailability (SUBA)-itraconazole oral capsules for patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida. HedgePath Pharmaceuticals, Inc. is a subsidiary of Mayne Pharma Ventures Pty Ltd.

InterCure stock logo

InterCure NASDAQ:INCR

$1.57 +0.07 (+4.67%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$1.54 -0.03 (-1.59%)
As of 08:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

VolitionRx stock logo

VolitionRx NYSE:VNRX

$0.71 +0.03 (+4.80%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$0.73 +0.02 (+3.30%)
As of 08:44 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.